Tag: pfizer

Categories
-Top News COVID-19

‘Moderna more troublesome than Pfizer’

The study, published in the journal JAMA, analysed reports collected via a Centers for Disease Control and Prevention (CDC) programme called v-safe that tracks side effects in vaccine recipients….reports Asian Lite News

In a first, a new study has pointed out that those taking the Moderna vaccine have reported more side effects than people who get the Pfizer/BioNTech jabs.

The study, published in the journal JAMA, analysed reports collected via a Centers for Disease Control and Prevention (CDC) programme called v-safe that tracks side effects in vaccine recipients.

A total of 3,643,918 people were enrolled in v-safe and completed at least one health survey within seven days following their first vaccine dose before February 21, and 1,920,872 v-safe participants reported receiving a second vaccine dose and completed at least one daily health survey within seven days following the second dose.

Nearly 70 per cent of those said they had some kind of injection site reaction, like pain or swelling, and half had generalised reaction like fatigue or chills.

“A greater percentage of participants who received the Moderna vaccine, compared with the Pfizer-BioNTech vaccine, reported reactogenicity; this pattern was more pronounced after the second dose,” the researchers noted.

Also read:CDC reveals Pfizer, Moderna jabs effective in real world

Reactogenicity refers to a subset of reactions that occur soon after vaccination.

People who got a Moderna shot were more likely to have a side effect — 73 per cent had an injection site reaction, compared with 65 per cent of people who had a Pfizer/BioNTech dose.

Nearly 51 per cent of Moderna recipients had full-body symptoms, compared with 48 per cent of people who got the Pfizer/BioNTech shot.

The gap widened after the second dose.

Almost 82 per cent of people getting their second Moderna shot had injection site pain versus just under 69 per cent of people with Pfizer/BioNTech, reports The Verge.

“Overall, 74 per cent of people said they had general reactions after their Moderna shot, compared with 64 per cent of people getting Pfizer/BioNTech,” the report said on Tuesday.

Zulema Riquelme, a 46-year-old nursing technician, receives a shot of the COVID-19 vaccine at the Metropolitan Hospital in Santiago, Chile

People over 65 were also less likely to have side effects than people under 65, regardless of which vaccine they received.

“Data from millions of v-safe participants indicate that injection site pain is common after both the first and second doses of either mRNA-based vaccine,” the study noted.

Systemic reactions, including fatigue, headache, myalgia, chills, fever, and joint pain, occurred in participants after the first dose, although they were more frequently reported after the second dose among both Pfizer-BioNTech and Moderna vaccine recipients.

Also read:CDC reveals Pfizer, Moderna jabs effective in real world

Categories
-Top News World News

CDC reveals Pfizer, Moderna jabs effective in real world

It takes about two weeks following each dose of vaccine for the body to produce antibodies that protect against infection…reports Asian Lite News.

Pfizer-BioNTech and Moderna’s Covid-19 vaccines are highly effective in preventing infections in real world conditions, says a new study by the US Centers for Disease Control and Prevention (CDC).

Results showed that following the second dose of vaccine, risk of infection was reduced by 90 per cent two or more weeks after vaccination, the CDC said on Monday.

Following a single dose of either vaccine, the participants’ risk of infection with SARS-CoV-2 was reduced by 80 per cent two or more weeks after vaccination.

The study looked at the effectiveness of Pfizer-BioNTech and Moderna mRNA vaccines in preventing SARS-CoV-2 infections among nearly 4,000 participants in six US states over a 13-week period from December 14, 2020 to March 13, 2021.

It takes about two weeks following each dose of vaccine for the body to produce antibodies that protect against infection.

As a result, people are considered “partially vaccinated” two weeks after their first dose of mRNA (Messenger RNA) vaccine and “fully vaccinated” two weeks after their second dose.

These new vaccine effectiveness findings are consistent with those from phase-3 clinical trials conducted with the vaccines before they received Emergency Use Authorisations from the US Food and Drug Administration (FDA).

Those clinical trials evaluated vaccine efficacy against Covid-19 disease, while this study evaluated vaccine effectiveness against infection, including infections that did not result in symptoms.

Zulema Riquelme, a 46-year-old nursing technician, receives a shot of the COVID-19 vaccine at the Metropolitan Hospital in Santiago, Chile

“This study shows that our national vaccination efforts are working. The authorised mRNA Covid-19 vaccines provided early, substantial real-world protection against infection for our nation’s health care personnel, first responders, and other frontline essential workers,” CDC Director Rochelle Walensky, said in a statement.

This study also provided positive news about partial (one-dose) vaccination.

The estimate of 80 per cent effectiveness in this study is consistent with other recent studies following the first dose of Pfizer-BioNTech vaccine among health care providers.

children walking in street during Covid 19 surge in us

Studies conducted in the UK and Israel showed that one dose was about 70 per cent and 60 per cent effective, respectively, against SARS-CoV-2 infection.

The current results provide reassurance that people start to develop protection from the vaccine two weeks after their first dose.

The greatest protection was seen among those who had received both recommended doses of the vaccine.

Also Read-UAE begins Covid-19 vaccine production

Read More-Germany limits use of AstraZeneca jabs

Categories
-Top News COVID-19

‘Pfizer vax less potent against S. African variant’

For the study, the research team looked at the effectiveness of the vaccine against the original viral strain, the UK and the South African variants, as well as strains that harbour combined changes in the viral spike…reports Asian Lite News

The Pfizer-BioNTech Covid-19 vaccine is moderately less effective against the South African variant, suggests a study.

The findings, published in the journal Cell Host & Microbe, showed that the vaccine is effective against the original SARS-CoV-2 strain and the UK variant, but provides weakened protection against the South African variant and the combined UK-South African variants.

“Our findings show that future variants could necessitate a modified vaccine as the virus mutates to increase its infectivity,” said researcher Ran Taubea from the Ben-Gurion University of the Negev in Israel.

For the study, the research team looked at the effectiveness of the vaccine against the original viral strain, the UK and the South African variants, as well as strains that harbour combined changes in the viral spike.

They are continuing to test other circulating variants as they constantly emerge with the hope to identify potentially risky mutations that can compromise the vaccine, the study indicated.

The research team also compared neutralising antibody levels following administration of one and two doses of the vaccine, as opposed to levels in patients that have recovered from Covid-19.A

The team found that vaccination provided optimal levels of protection, when compared to the lower levels of protection that were observed in recovered patients.

A recent study, published in the journal Nature, also indicated that Covid-19 vaccines developed by Moderna and Pfizer-BioNTech significantly appear less effective against the Covid variant that first emerged in South Africa.
Also read:EU warns of vaccine export curbs